Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer (MATRIX EG)
Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma
Sponsor: Merck KGaA, Darmstadt, Germany
A PHASE2 clinical study on Esophageal Cancer and Gastric Cancer, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Barcelona, Spain , Bern, Switzerland , Bournemouth, United Kingdom , Cadiz, Spain , Cambridge, United Kingdom , Chelmsford, United Kingdom , Essen, Germany , Geneva, Switzerland , Guildford, United Kingdom and 11 more locations